Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
NCT07152223Withdrawn
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of BG2205 in Connective tissue disease (CTD), sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoint: Evaluation of Safety up to 2 years. Planned start Aug 2025; status: withdrawn.
02
Drugs
BG2205
03
Conditions
Connective tissue disease (CTD)
Beyond the preview
Go deeper on NCT07152223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152223.